

**a. Original publications**

1. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation.  
**Azzola A, Havryk A, Chhajed P, Hostettler K, Black J, Johnson P, Roth M, Glanville A, Tamm M.**  
Transplantation. 2004 Jan 27;77(2):275-80.  
Impact Factor: 6.2
2. Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection.  
**Azzola A, Passweg JR, Habicht JM, Bubendorf L, Tamm M, Gratwohl A, Eich G.**  
J Clin Microbiol. 2004 Oct;42(10):4805-8.  
Impact Factor: 9.4
3. Therapeutic bronchoscopy interventions before surgical resection of lung cancer.  
**Chhajed PN, Eberhardt R, Dienemann H, Azzola A, Brutsche MH, Tamm M, Herth FJ.**  
Ann Thorac Surg. 2006 May;81(5):1839-43.  
Impact Factor: 4.5
4. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study.  
**Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M.**  
Eur Respir J. 2009 Dec;34(6):1364-75.  
Impact Factor: 24.9
5. Six-minute walk test enhanced by mobile telemetric cardiopulmonary monitoring.  
**Tueller C, Kern L, Azzola A, Baty F, Condrau S, Wiegand J, Tamm M, Brutsche M.**  
Respiration. 2010;80(5):410-8.  
Impact Factor: 3.966
6. Fatal cerebral air embolism following uneventful flexible bronchoscopy.  
**Azzola A, von Garnier C, Chhajed PN, Schirp U, Tamm M.**  
Respiration. 2010;80(6):569-72.  
Impact Factor: 3.966
7. Therapeutic bronchoscopy for malignant airway stenoses: choice of modality and survival.  
**Chhajed PN, Somandin S, Baty F, Mehta AJ, Azzola A, Leuppi J, Tamm M, Brutsche MH.**  
J Cancer Res Ther. 2010 Apr-Jun;6(2):204-9.  
Impact Factor: 1.3
8. Sleep-disordered breathing in acute ischemic stroke and transient ischemic attack: effects on short- and long-term outcome and efficacy of treatment with continuous positive airways pressure--rationale and design of the SAS CARE study.  
**Cereda CW, Petrini L, Azzola A, Ciccone A, Fischer U, Gallino A, Györik S, Gugger M, Mattis J, Lavie L, Limoni C, Nobili L, Manconi M, Ott S, Pons M, Bassetti CL.**  
Int J Stroke. 2012 Oct;7(7):597-603  
Impact Factor: 6.7

9. Oxygen kinetics during 6-minute walk tests in patients with cardiovascular and pulmonary disease.  
*Kern L, Condrau S, Baty F, Wiegand J, van Gestel AJ, **Azzola A**, Tamm M, Brutsche M.*  
BMC Pulm Med. 2014 Oct 29;14:167  
Impact Factor: 3.32
  
10. Long-term data from the Swiss pulmonary hypertension registry.  
*Mueller-Mottet S, Stricker H, Domenighetti G, **Azzola A**, Geiser T, Schwerzmann M, Weilenmann D, Schoch O, Fellrath JM, Rochat T, Lador F, Beghetti M, Nicod L, Aubert JD, Popov V, Speich R, Keusch S, Hasler E, Huber LC, Grendelmeier P, Tamm M, Ulrich S.*  
Respiration. 2015;89(2):127-40  
Impact Factor: 3.966
  
11. Extra-anatomical VATS lung resection: the outpatient experience with the aid of a digital chest drain device.  
*Cafarotti S, Cusumano G, Giuliani M, Matarelli E, Carboni GL, Schneiter D, **Azzola A**\*- Pneumoclub Ticino CH\*, Dutly AE (\*member of).*  
Eur Rev Med Pharmacol Sci. 2015 Oct;19(20):3850-4.  
Impact Factor: 3.3
  
12. The one repetition maximum test and the sit-to-stand test in the assessment of a specific pulmonary rehabilitation program on peripheral muscle strength in COPD patients.  
*Zanini A, Aiello M, Cherubino F, Zampogna E, **Azzola A**, Chetta A, Spanevello A.*  
Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2423-30  
Impact Factor: 2.9
  
13. Indacaterol and Glycopyrronium versus Indacaterol on Body Plethysmography Measurements in COPD - A randomised controlled study  
*Salomon J; Stolz D; Domenighetti G; Frey JG; Turk AJ; **Azzola A**; Sigrist Th; Fitting JW; Schmidt U; Geiser Th; Wild C; Kostikas K; Clemens A; Brutsche M*  
Respiratory Research 2017;18:13  
Impact Factor: 7.162
  
14. Idiopathic pulmonary fibrosis in Switzerland - Diagnosis and Treatment. Position of the Working Group for Interstitial and rare lung diseases of the Swiss Respiratory Society  
*Funke-Chambour M., **Azzola A.**, Adler D., Barazzone-Argiroffo C., Benden C., Boehler A., Bridevaux P.-O., Brutsche M., Clarenbach C., Hostettler K., Kleiner-Finger R., Nicod L.P., Soccia P.M., Tamm M., Geiser T, Lazor R*  
Respiration. 2017; 93(5):363-378  
Impact Factor: 3.966
  
15. Invasive hemodynamic evaluation of the pulmonary circulation in pulmonary hypertension  
*Pagnamenta A, **Azzola A**, Beghetti M, Lador F; on behalf of The Swiss Society of Pulmonary Hypertension)*  
Swiss Med Wkly. 2017 Jul 19;147  
Impact Factor: 4.203

16. Modern invasive hemodynamic assessment of pulmonary hypertension  
*Pagnamenta A, Lador F, **Azzola A**, Beghetti M*  
Respiration. 2018;95(3):201-211.  
Impact Factor: 3.966
  
17. Development and initial evaluation of a novel ultra-portable virtual reality bronchoscopy simulator: the Computer Airway Simulation System (CASS Simulator).  
*Casso G, Schoettker P, Savoldelli GL, **Azzola A**, Cassina T*  
Anesth Analg. 2018 Feb 23  
Impact Factor: 6.627
  
18. Multicenter, observational screening survey for the detection of chronic thromboembolic pulmonary hypertension following pulmonary embolism  
*Coquoz N, Weilenmann D, Stolz D, Popov V, **Azzola A**, Fellrath JM, Stricker H, Pagnamenta A, Ott S, Ulrich S, Györik S, Aubert JD*  
Eur Respir J. 2018 Apr 4;51(4)  
Impact Factor: 24.9
  
19. Hypertension pulmonaire pour le généraliste en 2018.  
**Azzola A.**  
Rev Med Suisse. 2018 Jan 24;14(591):212-215  
Impact Factor: 0.132
  
20. Die SGPH: ein Expertennetzwerk im Einsatz gegen pulmonalarterielle Hypertonie  
Lador F, **Azzola A.**, Ulrich S.  
Schweiz Aerzteztg. 2018;99(49): 1736-1737  
Impact Factor: 0.132
  
21. Minimum clinically important difference in 30-s Sit-to-Stand test after pulmonary rehabilitation in subjects with COPD  
*Zanini A, Crisafulli E, D'Andria M, Gregorini C, Cherubino F, Zampogna E, **Azzola A**, Spanevello A, Schiavone N, Chetta A*  
Respir Care. 2019 Jul 3; [Epub ahead of print]  
Impact Factor: 2.339
  
22. COVID-19 and the role of imaging: early experiences in Central Switzerland  
*Fechner C, Strobel K, Treumann Th, Sonderegger B, **Azzola A**, Fornaro J, Schradling S, Roos JE*  
Swiss Med Wkly. 2020 Jun 22;150  
Impact Factor: 4.203
  
23. Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry  
*Appenzeller P, Lichtblau M, Berlier C, Aubert JD, **Azzola A**, Fellrath JM, Geiser T, Lador F, Pohle S, Opitz I, Schwerzmann M, Stricker H, Tamm M, Saxer S, Ulrich S.*  
Pulm Circ. 2022 Jan 5;12(1):e12001.  
Impact Factor: 2.886
  
24. The Swiss Approach - feasibility of a national low-dose CT lung cancer screening program  
*Jungblut L, von Gamier C, Puhan M, Tomonaga Y, Kaufmann C, **Azzola A**, Bürgi U, Bremerich J, Brutsche M, Ott S, Frauenfelder T et al..*  
Swiss Med Wkly. 2022 Apr 14;152(15-16)  
Impact Factor: 4.203

25. Swiss Hypersensitivity Pneumonitis Exposure Questionnaire: A Regionally Adapted and Easy-To-Use Aide for Patients and Clinicians.  
*Pohle S, Guler SA, Hostettler KE, Clarenbach C, Fellrath JM, **Azzola A**, Adler D, Scholtze D, Pavlov N, Ulrich S, Györik S, Schoch OD, Baty F, Funke-Chambour M, Brutsche M*; Swiss Special Interest Group Interstitial and Rare Lung Diseases; Swiss Society of Pulmonology.  
Respiration. 2023;102(6):465-468

Impact Factor: 3.966

### **b. Case reports**

1. Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors.  
*Aschmann YZ, Kummer O, Linka A, Wenk M, **Azzola A**, Bodmer M, Krähenbühl S, Haschke M.*  
Ther Drug Monit. 2008 Feb;30(1):130-4  
Impact Factor: 3.1184
2. Images in clinical medicine. Lichtenberg figures.  
*Schmidhauser T, **Azzola A***  
N Engl J Med. 2011 Dec 29;365(26):e49.  
Impact Factor: 176.08
3. 'Bubbles in the brain': systemic air embolism syndrome from an atrial - oesophageal fistula.  
*Cereda C, Staedler C, Moschovitis G, Caronni F, Bassetti CL, **Azzola A***  
Emerg Med J. 2011 May 28;(5):455.  
Impact Factor: 3.814
4. Unusual case of splenic sarcoidosis without morphological lesions detected by PET-CT in a patient with breast cancer: functional imaging between pitfalls and therapeutic guide  
*Paone G, Di Lascio S, **Azzola A**, Mazzucchelli L, Pagani O*  
Ecancermedicalsecience. 2017 Sep 8;11:766  
Impact Factor: 0.665
5. Bronchoalveolar lavage-detected SARS-CoV-2 infection in presence of serial negative nasopharyngeal swabs  
*Caci G, Minervini F, Fechner C, Ross JE, Obermann EC, **Azzola A***  
Ann Transl Med. 2021 Apr 9;(7):583.  
Impact Factor: 3.616
6. Vorgeschädigte Lunge mit rezidivierenden Infekten  
*Dörig S., Kaiser Ph, **Azzola A**.*  
Swiss Med Forum. 2024;24(04):38-40  
Impact Factor: 0.6

### **c. Other publications**

1. Publications of the ProHOSP study group, as member of the Data Safety and Monitoring Board
- Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial.  
BMC Health Serv Res. 2007  
Impact Factor: 2.908

- Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009 Sep 9;302(10):1059-66. Impact Factor: 120.7
- Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. BMC Pulm Med. 2010 Mar 11;10:12. Impact Factor: 3.32
- Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010 Jul;138(1):121-9. Impact Factor: 10.1
- Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14(3):R106. Impact Factor: 8.8
- Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study. Virulence. 2010 Mar-Apr;1(2):88-92. Impact Factor: 5.428
- Predictors for length of hospital stay in patients with community-acquired pneumonia: results from a Swiss multicenter study. BMC Pulm Med. 2012 May 20;12:21. Impact Factor: 3.32
- Effect of hyperglycaemia on inflammatory and stress responses and clinical outcome of pneumonia in non-critical-care inpatients: results from an observational cohort study. Diabetologia. 2014 Feb;57(2):275-84. Impact Factor: 8.2
- Hyponatremia and anti-diuretic hormone in Legionnaires' disease. BMC Infect Dis. 2013 Dec 11;13:585. Impact Factor: 3.7
- Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol. 2014 Aug 20;175(3):464-72. Impact Factor: 3.5
- Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients. BMC Anesthesiol. 2014 Nov 15;14:102. Impact Factor: 2.376

#### **d. Peer reviewed manuscripts**

1. Diagnostic value of daily endotracheal aspirate cultures for the therapeutic management of ventilator associated pneumonia.  
**Azzola A, Tamm M, Scheidegger M.** (AJRCCM 2003, IF 30.528)
2. Increased CTGF expression in fibroblasts derived from patients with usual interstitial pneumonia (UIP = idiopathic pulmonary fibrosis)  
**Havryk A, Azzola A, Chhajed P, Black J, Johnson P, Roth M, Glanville A, Tamm M..** (AJRCCM 2002, IF 30.528)
3. Eosinophils pneumonia after radiation therapy for breast cancer  
**Riglietti A, Pons M, Poletti, Azzola A** (ERJ 2010, IF 24.9)